Kura Oncology's Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society's Pediatric Acute Leukemia (PedAL) Master Clinical Trial

SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and The Leukemia & Lymphoma Society (LLS), the largest private funder of blood cancer research, today announced a clinical collaboration to evaluate Kura’s menin inhibitor, ziftomenib, in combination with chemotherapy in pediatric patients with relapsed/refractory KMT2A-rearranged, NUP98-

Related Keywords

New Zealand ,Germany ,Spain ,Netherlands ,Utrecht ,United States ,Australia ,Canada ,America ,Dutch ,Gwen Nichols ,Alexandra Weingarten ,Ryan Mcdonald ,Mollie Leoni ,Kura Oncology Inc ,Science Communications ,Instagram ,Drug Administration ,Nasdaq ,Linkedin ,Fast Company ,Leukemia Lymphoma Society ,Exchange Commission ,Clinical Development ,Facebook ,Information Resource Center ,Corporate Communications ,Lymphoma Society ,Executive Vice President ,North America ,Pediatric Oncology ,Pediatric Acute Leukemia ,Dream Project ,Chief Medical Officer ,Orphan Drug Designation ,Pediatric Acute Leukemia Master Trial ,Screening Trial ,Rye Brook ,That Matter ,Vice President ,Investor Relations ,Blood Cancer ,Acute Leukemia ,Clinical Trial ,Treatment Of Cancer ,Ls ,Pediatric Patients ,Kura Oncology ,Rincess Máxima ,Clinical Collaboration ,Children ,